Elevated Vitamin K Levels from Medical Nutrition Support

Parenteral Nutrition (PN)

• Lipid emulsions used in PN are a major source of vitamin K, containing phylloquinone concentrations that range from approximately 6 µg up to 300 µg per 100 g of lipid material【1】.
• Providing a weekly intravenous supply of 250–500 µg phylloquinone from PN lipids alone is sufficient to restore and maintain normal plasma vitamin K concentrations in adults【1】.
• Adding adult multivitamin preparations to PN contributes an extra ≈150 µg of vitamin K, which not only meets daily requirements but also more effectively sustains the carboxylation status of non‑coagulation proteins【1】.

Enteral Nutrition (EN)

• Standard EN formulas deliver vitamin K at levels of roughly 3.5–20 µg per 100 kcal, generally meeting the recommended daily intake for most patients【1】.
• In patients receiving vitamin K antagonists (e.g., warfarin), EN can markedly affect anticoagulation response, necessitating adjustments to the anticoagulant dosing regimen【1】.

Anticoagulation Management

• For individuals on warfarin therapy, careful monitoring of all vitamin K sources is essential because PN lipid‑derived vitamin K doses exceeding 150 µg can lead to resistance to anticoagulant effects【1】.

Vitamin K1 Dosing Guidelines

Vitamin K1 Dosing for Newborns and Adults

• The American Academy of Pediatrics recommends a single intramuscular dose of 0.5 to 1.0 mg vitamin K1 for newborns within one hour of birth, while for adults, the recommended dose ranges from 2.5 to 10 mg for most indications, with up to 25-50 mg for severe cases 2
• For preterm infants on parenteral nutrition, the recommended dose is 10 μg/kg/day, as suggested by Clinical Nutrition guidelines 3, 4

Vitamin K1 Dosing for Adults

• Adults on parenteral nutrition should receive 200 μg/day of vitamin K1, according to Clinical Nutrition guidelines 3
• The maximum effect for IV administration of vitamin K1 occurs within 6-12 hours, while oral supplementation takes about 24 hours to reach full effect, as reported by Clinical Nutrition 5
• For patients on anticoagulant therapy, vitamin K administration may affect response to these medications, requiring monitoring of coagulation parameters, as recommended by Clinical Nutrition 5

Elevated Vitamin K in Adults: Causes, Safety Profile, and Clinical Management

Causes of Elevated Vitamin K

• Excessive vitamin K intake in adults is most often due to high‑dose supplementation (especially via parenteral or enteral nutrition) and consumption of vitamin K‑rich foods; natural forms (vitamin K1 and K2) do not cause toxicity. 6
• Dietary sources rich in vitamin K1 include leafy greens, cruciferous vegetables, asparagus, prunes, peas, and parsley. 6
• Daily oral supplementation leads to gradual accumulation because vitamin K is stored in body tissues. 7, 8

Safety Profile of Natural Vitamin K

• Neither vitamin K1 (phylloquinone) nor vitamin K2 (menaquinones) are linked to toxic effects, even at high intake levels. 6
• No adverse effects have been reported from supplementation with natural vitamin K forms. 6, 7, 8
• The body does not reach toxic concentrations from dietary or supplemental vitamin K; no upper safety limit has been established. 6
• Synthetic vitamin K3 (menadione) is highly toxic and can cause severe infantile conditions such as jaundice, hemolytic anemia, and kernicterus. 6
• Rare anaphylactoid reactions—including bronchospasm and cardiac arrest—have been observed after intravenous vitamin K1 administration for anticoagulation reversal; these events are related to the route of administration, not to elevated vitamin K levels per se. 6

Interaction with Vitamin K Antagonist Therapy

• In patients receiving vitamin K antagonists (e.g., warfarin), oral or parenteral vitamin K doses exceeding 150 µg can overcome the anticoagulant effect and produce resistance. 9

Monitoring Vitamin K Status

• Plasma/serum phylloquinone concentration is the primary laboratory marker for recent vitamin K intake. 6
• Levels below 0.15 mg/L denote deficiency; there is currently no defined upper threshold for toxicity. 6
• The under‑carboxylated prothrombin assay (PIVKA‑II) can evaluate functional vitamin K status but is not routinely employed in clinical practice. 6, 7